SLC5A2 and chronic kidney disease: The impact of kidney disease on the effect of SGLT2 inhibition on the progression of kidney disease observed in EMPA-KIDNEY is similar to that seen in other large placebo-controlled trials of SGLT2-inhibitors involving patients with CKD.3–5 A previous meta-analysis demonstrated that when standardized to the same definition of kidney disease progression, relative effect sizes are remarkably similar for a given primary cause of kidney disease.